Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 6.3% – Still a Buy?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) shares rose 6.3% during mid-day trading on Monday. The company traded as high as $9.79 and last traded at $9.65. Approximately 343,567 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 1,225,672 shares. The stock had previously closed at $9.08.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Cantor Fitzgerald reduced their price target on shares of Zevra Therapeutics from $25.00 to $19.00 and set an “overweight” rating on the stock in a research report on Friday, November 13th. HC Wainwright reissued a “buy” rating and issued a $26.00 target price on shares of Zevra Therapeutics in a research note on Thursday, August 20th. Citizens Jmp boosted their price target on shares of Zevra Therapeutics from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday, August 6th. BTIG Research cut their price target on Zevra Therapeutics from $24.00 to $21.00 and set a “buy” rating on the stock in a report on Friday, November 13th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Zevra Therapeutics in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Zevra Therapeutics has an average rating of “Buy” and an average target price of $23.86.

Get Our Latest Research Report on Zevra Therapeutics

Zevra Therapeutics Stock Up 1.6%

The firm’s 50-day moving average is $10.86 and its 200-day moving average is $10.84. The company has a market capitalization of $559.39 million, a PE ratio of 5.23 and a beta of 1.01.

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.16 by $0.10. The business had revenue of $37.76 million during the quarter, compared to analyst estimates of $37.08 million. Zevra Therapeutics had a return on equity of 54.64% and a net margin of 52.80%. As a group, equities research analysts predict that Zevra Therapeutics, Inc. will post 0.94 EPS for the current year.

Insider Buying and Selling at Zevra Therapeutics

In related news, CEO Neil McFarlane sold 20,000 shares of the stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $11.25, for a total transaction of $225,000.00. Following the completion of the sale, the chief executive officer owned 417,225 shares in the company, valued at approximately $4,693,781.25. This trade represents a 4.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.70% of the stock is currently owned by insiders.

Institutional Trading of Zevra Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Integrated Wealth Concepts LLC purchased a new position in Zevra Therapeutics during the second quarter valued at approximately $28,000. Fulcrum Asset Management LLP purchased a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at approximately $31,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Zevra Therapeutics during the 3rd quarter valued at about $33,000. State of Alaska Department of Revenue acquired a new position in shares of Zevra Therapeutics in the third quarter worth $44,000. Finally, State of Wyoming acquired a new position in Zevra Therapeutics during the 3rd quarter worth approximately $81,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

(Get Free Report)

Zevra Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for rare diseases. Its work includes research and development as well as bringing therapies to patients with limited treatment options. The company’s products include MIPLYFFA (arimoclomol), approved in the United States for neurological manifestations of Niemann-Pick disease type C, and OLPRUVA (sodium phenylbutyrate), a treatment for certain urea cycle disorders. Zevra also advances investigational therapies for rare and complex conditions.

Read More

Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.